Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126736
Filing Date
2024-11-14
Accepted
2024-11-14 07:30:29
Documents
88
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q itrm-20240930.htm   iXBRL 10-Q 2800095
2 EX-10.1 itrm-ex10_1.htm EX-10.1 498791
3 EX-31.1 itrm-ex31_1.htm EX-31.1 17017
4 EX-31.2 itrm-ex31_2.htm EX-31.2 17262
5 EX-32.1 itrm-ex32_1.htm EX-32.1 9991
6 EX-32.2 itrm-ex32_2.htm EX-32.2 9983
  Complete submission text file 0000950170-24-126736.txt   12193566

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itrm-20240930.xsd EX-101.SCH 1795587
91 EXTRACTED XBRL INSTANCE DOCUMENT itrm-20240930_htm.xml XML 1969291
Mailing Address FITZWILLIAM COURT, 1ST FLOOR LEESON CLOSE DUBLIN 2 L2 D02 YW24
Business Address FITZWILLIAM COURT, 1ST FLOOR LEESON CLOSE DUBLIN 2 L2 D02 YW24 (872) 225-6077
Iterum Therapeutics plc (Filer) CIK: 0001659323 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38503 | Film No.: 241457205
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)